[go: up one dir, main page]

DE60331925D1 - Krebstherapie mit ganzen glukan-teilchen und antikörpern - Google Patents

Krebstherapie mit ganzen glukan-teilchen und antikörpern

Info

Publication number
DE60331925D1
DE60331925D1 DE60331925T DE60331925T DE60331925D1 DE 60331925 D1 DE60331925 D1 DE 60331925D1 DE 60331925 T DE60331925 T DE 60331925T DE 60331925 T DE60331925 T DE 60331925T DE 60331925 D1 DE60331925 D1 DE 60331925D1
Authority
DE
Germany
Prior art keywords
glucan particles
whole glucan
antibodies
cancer therapy
immune system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60331925T
Other languages
English (en)
Inventor
Gary R Ostroff
Gordon D Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Biopolymer Engineering Inc
Original Assignee
University of Louisville Research Foundation ULRF
Biopolymer Engineering Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60331925(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Louisville Research Foundation ULRF, Biopolymer Engineering Inc filed Critical University of Louisville Research Foundation ULRF
Application granted granted Critical
Publication of DE60331925D1 publication Critical patent/DE60331925D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60331925T 2002-09-04 2003-09-04 Krebstherapie mit ganzen glukan-teilchen und antikörpern Expired - Lifetime DE60331925D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40812602P 2002-09-04 2002-09-04
PCT/US2003/027841 WO2004021994A2 (en) 2002-09-04 2003-09-04 Cancer therapy using whole glucan particles and antibodies

Publications (1)

Publication Number Publication Date
DE60331925D1 true DE60331925D1 (de) 2010-05-12

Family

ID=31978563

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60331925T Expired - Lifetime DE60331925D1 (de) 2002-09-04 2003-09-04 Krebstherapie mit ganzen glukan-teilchen und antikörpern

Country Status (9)

Country Link
US (3) US8883760B2 (de)
EP (3) EP1536820B2 (de)
JP (1) JP2006502167A (de)
CN (3) CN1939335A (de)
AT (1) ATE462437T1 (de)
AU (2) AU2003268486A1 (de)
CA (2) CA2496508C (de)
DE (1) DE60331925D1 (de)
WO (2) WO2004030613A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1545208A4 (de) 2002-08-13 2006-04-12 Biopolymer Engineering Inc Verfahren zur verwendung von beta-glucan als strahlenschutzmittel
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP1536820B2 (de) * 2002-09-04 2013-10-23 Biopolymer Engineering, Inc. Krebstherapie mit ganzen glukan-teilchen und antikörpern
EP2070546A1 (de) 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Vorbeugungsmaßnahmen/Heilmittel für Krebs
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
KR20070054246A (ko) * 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
EP1917019A2 (de) * 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Kombination eines beta-glucans und eines egf-rezeptor-antagonisten zur krebs- und infektionsbehandlung
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1984004A4 (de) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer Die therapie verstärkendes glucan
RU2490279C2 (ru) * 2006-06-15 2013-08-20 Байотера, Инк. Композиции глюкана
EP2062588A4 (de) * 2006-08-24 2011-06-08 Kirin Holdings Kk Zusammensetzung zur linderung eines hautzustands
US20080167268A1 (en) * 2006-09-01 2008-07-10 Jun Yan Particulate beta-glucan compositions for regulating dendritic cells
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
CA2704056A1 (en) 2007-10-29 2009-05-07 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2009103116A1 (en) * 2008-02-19 2009-08-27 Novogen Research Pty Ltd Ex vivo cell stimulation
US20120003178A1 (en) * 2008-02-19 2012-01-05 Novogen Research Pty Ltd Evaluating the therapeutic potential of a glucan
WO2013040027A1 (en) * 2011-09-12 2013-03-21 Baylor Research Institute Reprogramming immune environment in breast cancer via dendritic cells
AU2013257139B2 (en) * 2012-04-30 2018-02-22 Biothera, Inc. Beta-glucan immunotherapeutic methods
ES2743428T3 (es) 2012-05-07 2020-02-19 Kemin Ind Inc Proceso de múltiples etapas para la producción de un inmunomodulador
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
US9738731B2 (en) * 2013-03-08 2017-08-22 Tokyo University Of Science Foundation Lactic acid bacterium growth enhancer, regulatory T-cell number increasing agent, method of enhancing growth of lactic acid bacterium, method of increasing number of regulatory T-cells, method of evaluating regulatory T-cell number increasing effect, and method of evaluating lactic acid growth enhancing effect
EP2832360A1 (de) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharid zur Verwendung bei der Prävention der Bildung von Metastasen und/oder Rezidiven
AU2014357446B2 (en) * 2013-12-05 2020-05-07 Biothera, Inc. Beta-glucan assay methods
JP6797022B2 (ja) 2014-03-05 2020-12-09 オービス ヘルス ソリューションズ エルエルシー 酵母細胞壁粒子を用いたワクチン送達系
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
CN106687122B (zh) 2014-07-10 2020-11-10 百奥赛诺公司 β-葡聚糖与影响肿瘤微环境的抗癌剂的组合
EP3215163B1 (de) 2014-11-06 2021-03-10 Biothera, Inc. Die tumormikroumgebung beeinflussende verfahren und zusammensetzungen mit beta-glucan
US20180110853A1 (en) * 2016-10-21 2018-04-26 Wisconsin Alumni Research Foundation Vaccine Adjuvant
WO2018106645A1 (en) 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
WO2018106644A1 (en) * 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc ß-1,6-GLUCAN TRASTUZUMAB ANTIBODY CONJUGATES
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
US11559554B2 (en) 2017-04-10 2023-01-24 Kibow Biotech Inc. Multifiber prebiotic composition for digestive health, weight control, boosting immunity and improving health
JP7373152B2 (ja) 2018-03-13 2023-11-02 ヒベルセル， インコーポレイテッド β－グルカンおよびＣＤ４０アゴニスト併用免疫療法
US12377116B2 (en) * 2019-09-11 2025-08-05 Aureo Co., Ltd. Composition for enhancing effect of antibody drug
WO2021152497A1 (en) * 2020-01-29 2021-08-05 Pleuran, S.R.O. Beta-glucan for use in modulation of an immune response in a remission
EP3858362A1 (de) 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan zur verwendung bei der verbesserung der anti-tumor-immunität bei remission
US20240408196A1 (en) * 2021-05-24 2024-12-12 Frank Jordan Alkaline extraction of beta glucan compounds for use in anti-viral and immune therapies
KR20250110348A (ko) 2022-11-23 2025-07-18 제이제이알앤디 엘엘씨 암 세포독성 엑소좀 제형 및 암 치료에 사용되는 방법

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943247A (en) * 1972-05-22 1976-03-09 Kaken Kagaku Kabushiki Kaisha Treatment of bacterial infections with glucan compositions
US3903297A (en) * 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4138479A (en) * 1975-11-07 1979-02-06 Bayer Aktiengesellschaft Process for the preparation of immunopotentiating agents from components of yeast cell wall material
JPS5461112A (en) * 1977-10-24 1979-05-17 Ono Pharmaceut Co Ltd Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component
JPS58220989A (ja) 1982-06-14 1983-12-22 Diesel Kiki Co Ltd 可変容量式ベ−ン型圧縮機
SE456911B (sv) * 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
US5037972A (en) 1984-11-28 1991-08-06 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5250436A (en) * 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5082936A (en) * 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
CA1340080C (en) * 1985-03-11 1998-10-13 Dorothee Herlyn Human tumor therapy
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US5221616A (en) * 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
KR0141685B1 (ko) * 1988-09-01 1998-07-01 야마따니 와따루 참게 아메보사이트 라이세이트 g 인자 활성화 저해제
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5057503A (en) * 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
IT1232310B (it) 1989-09-04 1992-01-28 Consiglio Nazionale Ricerche Processo per la preparazione di un prodotto contenente glucano a partire da candida albicans bmm-12
CA2067159A1 (en) 1989-09-08 1991-03-09 Spiros Jamas Method for immune system activation
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
WO1991003495A1 (en) * 1989-09-08 1991-03-21 Alpha Beta Technology, Inc. Method for producing soluble glucans
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JP2911554B2 (ja) * 1990-06-25 1999-06-23 台糖株式会社 抗ウィルス剤
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3122454B2 (ja) * 1990-09-27 2001-01-09 生化学工業株式会社 カブトガニ・アメボサイト・ライセートの調製法
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
IT1256035B (it) 1992-08-10 1995-11-21 Consiglio Nazionale Ricerche Glucani ad attivita' immunostimolante
US5453124A (en) * 1992-12-30 1995-09-26 Texas Instruments Incorporated Programmable multizone gas injector for single-wafer semiconductor processing equipment
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
GB9420645D0 (en) * 1994-10-13 1994-11-30 Dow Chemical Co Non-linear stytrenic polymer compositions and articles prepared therefrom
US5576015A (en) * 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US6036946A (en) * 1997-12-24 2000-03-14 Shaklee Corporation Methods for protecting skin from damaging effects of ultraviolet light
CA2344166C (en) * 1998-09-14 2008-11-18 Nabi Compositions of .beta.-glucans and specific igiv
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1357919B1 (de) 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Glucan zur verbesserung der therapie
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
EP1545208A4 (de) * 2002-08-13 2006-04-12 Biopolymer Engineering Inc Verfahren zur verwendung von beta-glucan als strahlenschutzmittel
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP1536820B2 (de) 2002-09-04 2013-10-23 Biopolymer Engineering, Inc. Krebstherapie mit ganzen glukan-teilchen und antikörpern
CN1964722A (zh) 2004-05-10 2007-05-16 生物聚合物工程有限公司 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒

Also Published As

Publication number Publication date
AU2003268486A1 (en) 2004-03-29
US20150064199A1 (en) 2015-03-05
CN1939335A (zh) 2007-04-04
EP1536820B1 (de) 2010-03-31
CA2496508C (en) 2014-04-22
EP1536820A2 (de) 2005-06-08
US8883760B2 (en) 2014-11-11
US9522187B2 (en) 2016-12-20
EP1539194A2 (de) 2005-06-15
US20170056432A1 (en) 2017-03-02
CN1694715A (zh) 2005-11-09
WO2004021994A3 (en) 2004-08-12
AU2003268486A8 (en) 2004-03-29
JP2006502167A (ja) 2006-01-19
AU2003295326A8 (en) 2004-04-23
WO2004021994A2 (en) 2004-03-18
CA2496596C (en) 2016-06-28
CN100363054C (zh) 2008-01-23
CA2496508A1 (en) 2004-04-15
WO2004030613A2 (en) 2004-04-15
EP2181711A1 (de) 2010-05-05
EP1536820B2 (de) 2013-10-23
EP1539194A4 (de) 2007-06-13
AU2003295326A1 (en) 2004-04-23
CA2496596A1 (en) 2004-03-18
WO2004030613A3 (en) 2005-01-13
CN1694715B (zh) 2010-12-01
EP1536820A4 (de) 2007-06-20
US20060009419A1 (en) 2006-01-12
CN1697659A (zh) 2005-11-16
ATE462437T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
ATE462437T1 (de) Krebstherapie mit ganzen glukan-teilchen und antikörpern
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
WO2005081854A3 (en) Egf receptor epitope peptides and uses thereof
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
PL2135881T3 (pl) Przeciwciała wiążące się z antygenem TAT10772 związanym z nowotworem, do diagnozowania i leczenia nowotworu
TW201712034A (en) Anti-PD-L1 antibodies and their use to enhance t-cell function
NO20016007D0 (no) Rekombinant anti-CD40-antistoff og anvendelser derav
MXPA05012723A (es) Tratamiento con anticuerpos anti-vgf.
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
IL188594A0 (en) Anti-ccr7 receptor antibodies for the treatment of cancer
WO2011070214A8 (es) Conjugados y composiciones para inmunoterapia y tratamiento anti-tumoral
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
EP3674321A3 (de) Anti-met-antikörper und verwendungen davon
MX2021002605A (es) Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer.
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
WO2004071404A3 (en) Use of il-6 antagonists in combination with steroids to enhance apoptosis
BRPI0515604A (pt) método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada
WO2007144046A3 (de) Mittel zur behandlung von malignen erkrankungen
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
WO2006085895A3 (en) Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
MX2022004086A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos.
MX2024006212A (es) Métodos para usar agonistas del rar? para tratamiento del cáncer.
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos

Legal Events

Date Code Title Description
8363 Opposition against the patent